Non-Langerhans cell histiocytosis

Non-Langerhans cell histiocytosis (NLCH) refers to a heterogeneous group of rare disorders characterized by the accumulation and proliferation of histiocytes (tissue macrophages) that are distinct from Langerhans cells. Unlike Langerhans cell histiocytosis, the abnormal cells in NLCH do not express CD1a or langerin (CD207) and lack Birbeck granules on electron microscopy. This group encompasses several distinct entities, including Erdheim-Chester disease, Rosai-Dorfman disease (sinus histiocytosis with massive lymphadenopathy), juvenile xanthogranuloma, and other rarer subtypes. The clinical manifestations of NLCH vary widely depending on the specific subtype and the organs involved. Affected body systems can include the skin (papules, nodules, xanthomas), bones (osteosclerotic or osteolytic lesions), central nervous system (diabetes insipidus, cerebellar ataxia), cardiovascular system (periaortic fibrosis), lungs (interstitial infiltrates), retroperitoneum, orbits, and liver. Some forms are self-limiting, particularly in children (such as juvenile xanthogranuloma), while others can be progressive and life-threatening, particularly when vital organs are involved. Treatment depends on the specific subtype, extent of disease, and organ involvement. Observation alone may be appropriate for limited, self-resolving forms. For progressive or multisystem disease, treatment options include corticosteroids, interferon-alpha, cladribine, and other chemotherapeutic agents. The discovery of activating mutations in the MAPK/ERK signaling pathway (particularly BRAF V600E) in several forms of NLCH has led to the use of targeted therapies such as BRAF inhibitors (vemurafenib) and MEK inhibitors, which have shown significant clinical benefit in refractory cases. Surgical intervention or radiation therapy may be considered for localized disease. Prognosis varies considerably across subtypes and is largely determined by the extent and location of organ involvement.

Common questions about Non-Langerhans cell histiocytosis